Paul Rickey

Paul Rickey is the Chief Financial Officer at Braveheart Bio. He has deep experience in private and public company operations, finance, corporate development, and strategic planning and has proven success in early-stage financing, reverse mergers, IPOs, and M&A transactions. He previously served as CFO of Alpine Immune Sciences from 2017 through its acquisition by Vertex Pharmaceuticals in June 2024. From 2006 to 2017, Paul held finance and operating roles at public and private life sciences companies, including Sound Pharmaceuticals, Immune Design, and Northstar Neuroscience. He began his career at Ernst & Young in 2001 and earned both a BA and a Master of Professional Accounting from the University of Washington. Paul is a Certified Public Accountant (inactive).